211 related articles for article (PubMed ID: 32808250)
21. CAC score as a possible criterion for administration of angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers: the MultiEthnic Study of Atherosclerosis.
Darabian S; Luo Y; Homat A; Khosraviani K; Wong N; Zeb I; Nasir K; Budoff MJ
Coron Artery Dis; 2015 Dec; 26(8):678-85. PubMed ID: 26398149
[TBL] [Abstract][Full Text] [Related]
22. Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction.
Korhonen MJ; Robinson JG; Annis IE; Hickson RP; Bell JS; Hartikainen J; Fang G
J Am Coll Cardiol; 2017 Sep; 70(13):1543-1554. PubMed ID: 28935030
[TBL] [Abstract][Full Text] [Related]
23. Primary prevention of myocardial infarction with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertensive patients with rheumatoid arthritis-A nationwide cohort study.
Lin TT; Wu CK; Liao MT; Yang YH; Chen PC; Yeih DF; Lin LY
PLoS One; 2017; 12(12):e0188720. PubMed ID: 29216228
[TBL] [Abstract][Full Text] [Related]
24. Patient-Important Adverse Events of β-blockers in Frail Older Adults after Acute Myocardial Infarction.
Zullo AR; Olean M; Berry SD; Lee Y; Tjia J; Steinman MA
J Gerontol A Biol Sci Med Sci; 2019 Jul; 74(8):1277-1281. PubMed ID: 30137259
[TBL] [Abstract][Full Text] [Related]
25. Treatment with Optimal Dose Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Has a Positive Effect on Long-Term Survival in Older Individuals (Aged >70 Years) and Octogenarians with Systolic Heart Failure.
Sargento L; Simões AV; Longo S; Lousada N; Dos Reis RP
Drugs Aging; 2016 Sep; 33(9):675-83. PubMed ID: 27568454
[TBL] [Abstract][Full Text] [Related]
26. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H
Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265
[TBL] [Abstract][Full Text] [Related]
27. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk.
Potier L; Roussel R; Elbez Y; Marre M; Zeymer U; Reid CM; Ohman M; Eagle KA; Bhatt DL; Steg PG;
Heart; 2017 Sep; 103(17):1339-1346. PubMed ID: 28285267
[TBL] [Abstract][Full Text] [Related]
28. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study.
Ho CM; Lee CH; Lee MC; Zhang JF; Wang JY; Hu RH; Lee PH
BMC Cancer; 2018 Apr; 18(1):401. PubMed ID: 29631561
[TBL] [Abstract][Full Text] [Related]
29. The Divergent Cardiovascular Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Myocardial Infarction and Death.
Strauss MH; Hall AS
Prog Cardiovasc Dis; 2016; 58(5):473-82. PubMed ID: 26586276
[TBL] [Abstract][Full Text] [Related]
30. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare System.
An J; Wei R; Zhou H; Luong TQ; Gould MK; Mefford MT; Harrison TN; Creekmur B; Lee MS; Sim JJ; Brettler JW; Martin JP; Ong-Su AL; Reynolds K
J Am Heart Assoc; 2021 Feb; 10(3):e019669. PubMed ID: 33307964
[TBL] [Abstract][Full Text] [Related]
31. Renin-Angiotensin System Blockade and Risk of Heart Failure After Myocardial Infarction Based on Left Ventricular Ejection Fraction: A Retrospective Cohort Study.
Cespón-Fernández M; Raposeiras-Roubín S; Abu-Assi E; Manzano-Fernández S; Flores-Blanco P; Barreiro-Pardal C; Castiñeira-Busto M; Muñoz-Pousa I; López-Rodríguez E; Caneiro-Queija B; Cobas-Paz R; Fernández-Barbeira S; Domínguez-Erquicia P; Domínguez-Rodríguez LM; López-Cuenca Á; Gómez-Molina M; Baz-Alonso JA; Calvo-Iglesias F; Valdés-Chávarri M; Íñiguez-Romo A
Am J Cardiovasc Drugs; 2019 Oct; 19(5):487-495. PubMed ID: 30924021
[TBL] [Abstract][Full Text] [Related]
32. Accepting Medication Therapy Management Recommendations to Add ACEIs or ARBs in Diabetes Care.
Hurwitz JT; Grizzle AJ; Augustine J; Rehfeld R; Wild A; Abraham I
J Manag Care Spec Pharm; 2016 Jan; 22(1):40-8. PubMed ID: 27015050
[TBL] [Abstract][Full Text] [Related]
33. Association Between Preadmission Functional Status and Use and Effectiveness of Secondary Prevention Medications in Elderly Survivors of Acute Myocardial Infarction.
Chrischilles EA; Schneider KM; Schroeder MC; Letuchy E; Wallace RB; Robinson JG; Brooks JM
J Am Geriatr Soc; 2016 Mar; 64(3):526-35. PubMed ID: 26928940
[TBL] [Abstract][Full Text] [Related]
34. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in hypertensive patients with myocardial infarction or heart failure: a systematic review and meta-analysis.
Ohtsubo T; Shibata R; Kai H; Okamoto R; Kumagai E; Kawano H; Fujiwara A; Kitazono T; Murohara T; Arima H
Hypertens Res; 2019 May; 42(5):641-649. PubMed ID: 30948834
[TBL] [Abstract][Full Text] [Related]
35. Preadmission Antihypertensive Drug Use and Sepsis Outcome: Impact of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs).
Hsieh MS; How CK; Hsieh VC; Chen PC
Shock; 2020 Apr; 53(4):407-415. PubMed ID: 31135703
[TBL] [Abstract][Full Text] [Related]
36. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
Kuan YC; Huang KW; Yen DJ; Hu CJ; Lin CL; Kao CH
Int J Cardiol; 2016 Oct; 220():462-6. PubMed ID: 27390970
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study.
Kim JH; Baek YH; Lee H; Choe YJ; Shin HJ; Shin JY
Epidemiol Health; 2021; 43():e2021004. PubMed ID: 33445824
[TBL] [Abstract][Full Text] [Related]
38. Mortality benefit of long-term angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after successful percutaneous coronary intervention in non-ST elevation acute myocardial infarction.
González-Cambeiro MC; López-López A; Abu-Assi E; Raposeiras-Roubín S; Peña-Gil C; García-Acuña J; González-Juanatey R
Rev Port Cardiol; 2016 Dec; 35(12):645-653. PubMed ID: 27865680
[TBL] [Abstract][Full Text] [Related]
39. Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction.
Arnold SV; Spertus JA; Masoudi FA; Daugherty SL; Maddox TM; Li Y; Dodson JA; Chan PS
J Am Coll Cardiol; 2013 Nov; 62(19):1791-801. PubMed ID: 23973701
[TBL] [Abstract][Full Text] [Related]
40. Patterns of use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers among patients with acute myocardial infarction in China from 2001 to 2011: China PEACE-Retrospective AMI Study.
Liu J; Masoudi FA; Spertus JA; Wang Q; Murugiah K; Spatz ES; Li J; Li X; Ross JS; Krumholz HM; Jiang L;
J Am Heart Assoc; 2015 Feb; 4(2):. PubMed ID: 25713293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
